201 related articles for article (PubMed ID: 23775155)
21. Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis.
Marchetti C; De Felice F; Palaia I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
Crit Rev Oncol Hematol; 2016 Mar; 99():123-8. PubMed ID: 26748593
[TBL] [Abstract][Full Text] [Related]
22. Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis.
Gao S; Ma JJ; Lu C
Tumour Biol; 2014 Jan; 35(1):603-13. PubMed ID: 23959477
[TBL] [Abstract][Full Text] [Related]
23. Update on erythropoiesis-stimulating agents.
Goodnough LT; Shander A
Best Pract Res Clin Anaesthesiol; 2013 Mar; 27(1):121-9. PubMed ID: 23590921
[TBL] [Abstract][Full Text] [Related]
24. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy-induced anemia: the story of darbepoetin alfa.
Vansteenkiste J; Wauters I; Elliott S; Glaspy J; Hedenus M
Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876
[TBL] [Abstract][Full Text] [Related]
26. Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea.
Kang RY; Lee J; Lee YH; Lee HS; Jeong JH; Lee YJ
Int J Clin Pharm; 2012 Aug; 34(4):651-7. PubMed ID: 22729393
[TBL] [Abstract][Full Text] [Related]
27. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.
Tonelli M; Hemmelgarn B; Reiman T; Manns B; Reaume MN; Lloyd A; Wiebe N; Klarenbach S
CMAJ; 2009 May; 180(11):E62-71. PubMed ID: 19407261
[TBL] [Abstract][Full Text] [Related]
28. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
Bennett CL; Silver SM; Djulbegovic B; Samaras AT; Blau CA; Gleason KJ; Barnato SE; Elverman KM; Courtney DM; McKoy JM; Edwards BJ; Tigue CC; Raisch DW; Yarnold PR; Dorr DA; Kuzel TM; Tallman MS; Trifilio SM; West DP; Lai SY; Henke M
JAMA; 2008 Feb; 299(8):914-24. PubMed ID: 18314434
[TBL] [Abstract][Full Text] [Related]
29. Erythropoietin or darbepoetin for patients with cancer.
Tonia T; Mettler A; Robert N; Schwarzer G; Seidenfeld J; Weingart O; Hyde C; Engert A; Bohlius J
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003407. PubMed ID: 23235597
[TBL] [Abstract][Full Text] [Related]
30. Erythropoiesis-stimulating agents in oncology.
Glaspy JA
J Natl Compr Canc Netw; 2008 Jul; 6(6):565-75. PubMed ID: 18597710
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis.
Aapro M; Moebus V; Nitz U; O'Shaughnessy J; Pronzato P; Untch M; Tomita D; Bohac C; Leyland-Jones B
Ann Oncol; 2015 Apr; 26(4):688-695. PubMed ID: 25542926
[TBL] [Abstract][Full Text] [Related]
32. The effect of the APPRISE mandate on use of erythropoiesis-stimulating agents and transfusion rates in patients with ovarian cancer receiving chemotherapy.
Boone JD; Fauci JM; Walters CL; Whitworth JM; Bevis KS; Alvarez RD
Int J Gynecol Cancer; 2013 Feb; 23(2):367-71. PubMed ID: 23266649
[TBL] [Abstract][Full Text] [Related]
33. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
[TBL] [Abstract][Full Text] [Related]
34. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.
Hörl WH
Drugs; 2013 Feb; 73(2):117-30. PubMed ID: 23338536
[TBL] [Abstract][Full Text] [Related]
35. The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study.
Lai Y; Ye Z; Civan JM; Wang C; Cristofanilli M; Mu Z; Austin L; Palazzo JP; Myers RE; Yang H
Breast Cancer Res Treat; 2015 Sep; 153(2):407-16. PubMed ID: 26264468
[TBL] [Abstract][Full Text] [Related]
36. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
Hedley BD; Allan AL; Xenocostas A
Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
[TBL] [Abstract][Full Text] [Related]
37. Erythropoiesis-stimulating agents (ESAs), from chemotherapy-induced anemia to any cancer-related anemia?
Venturino A; Colloca G
Ann Oncol; 2010 Apr; 21(4):905-906. PubMed ID: 20032124
[No Abstract] [Full Text] [Related]
38. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
Rizzo JD; Brouwers M; Hurley P; Seidenfeld J; Arcasoy MO; Spivak JL; Bennett CL; Bohlius J; Evanchuk D; Goode MJ; Jakubowski AA; Regan DH; Somerfield MR; ;
J Clin Oncol; 2010 Nov; 28(33):4996-5010. PubMed ID: 20975064
[TBL] [Abstract][Full Text] [Related]
39. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
Rizzo JD; Brouwers M; Hurley P; Seidenfeld J; Arcasoy MO; Spivak JL; Bennett CL; Bohlius J; Evanchuk D; Goode MJ; Jakubowski AA; Regan DH; Somerfield MR;
Blood; 2010 Nov; 116(20):4045-59. PubMed ID: 20974674
[TBL] [Abstract][Full Text] [Related]
40. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
